Published Online: Friday, December 1, 2006

The dual-status Rx/OTC version of Plan B (levonorgestrel) is now available in pharmacies. Duramed Pharmaceuticals Inc, a wholly owned subsidiary of Barr Pharmaceuticals, began shipping the medication in mid November.

The dual-label product is approved for OTC sale for women aged 18 and older. The Plan B OTC/Rx version will be marketed as a single package, which will allow for an Rx label to be affixed to the package when dispensed to girls aged 17 and younger. Because Plan B remains a prescription product for adolescents, it will be available only in retail pharmacy outlets from behind the counter and under the supervision of a pharmacist.

The FDA granted Duramed 3-year exclusivity for Plan B, based on clinical studies conducted for OTC approval. The exclusivity is valid until August 2009.

Visit ePharmacy Times at for a related story on Plan B.

Latest Articles
The FDA has approved Boehringer Ingelheim’s oral direct thrombin inhibitor dabigatran etexilate mesylate (Pradaxa) for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who have had hip replacement surgery.
As a result of implementation difficulties, the FDA announced that it will extend the pharmacy certification deadline for the clozapine risk evaluation and mitigation strategy program.
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Latest Issues